Patient-Customized Oligonucleotide Therapy for a Rare Genetic DiseaseJin‐Kuk Kim, Timothy W. Yu, Iva Stojkovska et al.|New England Journal of Medicine|2019Cited by 823
Phase I Trial of Intramuscular Injection of a Recombinant Adeno-Associated Virus Serotype 2 <i>α</i> 1-Antitrypsin (AAT) Vector in AAT-Deficient AdultsMark Brantly, Terence R. Flotte, L. Terry Spencer et al.|Human Gene Therapy|2006Cited by 175
Characterization of a Recombinant Adeno-Associated Virus Type 2 Reference Standard MaterialMartin Lock, Richard O. Snyder, Susan P. McGorray et al.|Human Gene Therapy|2010Cited by 131
Development and Utility of an Internal Threshold Control (ITC) Real-Time PCR Assay for Exogenous DNA DetectionWeiyi Ni, Richard O. Snyder|PLoS ONE|2012Cited by 15
728. Safety and Bioactivity of rAAV2-hAAT in alpha-1 Antitrypsin-Deficient Patients in a Phase I Clinical TrialMark Brantly, Terence R. Flotte, Terry Spencer et al.|Molecular Therapy|2006Cited by 0